The Fc receptor-like protein 5 (FCRL5) on B cells has both an immunoreceptor tyrosine-based activation motif (ITAM)-like sequence and two consensus immunoreceptor tyrosine-based inhibitory motifs (ITIM) in its cytoplasmic region. To evaluate its signaling potential, we expressed constructs for chimeric molecules composed of the cytoplasmic region of FCRL5 and the extracellular and transmembrane regions of the IgG Fc receptor Fc␥RIIB in a B cell line lacking an endogenous Fc receptor. Coligation of this fusion protein with the B cell receptor (BCR) inhibited BCR-mediated calcium mobilization, intracellular tyrosine phosphorylation, and Erk kinase activation. Our mutational analysis indicated that, whereas tyrosines in both the inhibitory and activation motifs are phosphorylated after ligation, only those in ITIMs influence BCRmediated signaling. This FCRL5 inhibitory effect was mediated through dual ITIM recruitment of the SH2-containing protein tyrosine phosphatase, SHP-1, which in turn dephosphorylates the ITAM-based tyrosines in BCR Ig␣/Ig␤ heterodimers. An FCRL5 inhibitory effect on BCR signaling was likewise demonstrable for primary B cells. Although its ligand is presently unknown, we conclude that FCRL5 has the functional potential to serve as an inhibitory coreceptor on mature B cells in humans.
B
cell receptor (BCR) engagement initiates signaling cascades that lead to activation of the Ras-MAPK pathway, phosphatidylinositol-3-kinase, and phospholipase C ␥ (PLC␥) (1, 2) . The BCR triggering ultimately induces gene expression patterns that can promote cell activation, apoptosis, or anergy, depending upon the balance of enhancing and inhibitory influences that vary according to the stage in B cell differentiation (3) . Costimulatory or inhibitory coreceptors on B cells modulate BCR signaling to either enhance or attenuate downstream signaling cascades (4) . Inhibitory coreceptors may dampen BCR signaling via an immunoreceptor tyrosine-based inhibition motif (ITIM) in their cytoplasmic region. When tyrosine phosphorylated, the ITIMs recruit protein tyrosine phosphatases and lipid phosphatases via Src homology 2 (SH2) domain binding to achieve down-regulation or neutralization of BCR-induced activation (5) . Conversely, the costimulatory receptors may have their own cytoplasmic immunoreceptor tyrosinebased activation motifs (ITAM) or they may pair with a transmembrane protein containing one or more ITAMs, whose tyrosines are phosphorylated by src family kinases to allow the recruitment of signaling molecules that promote cellular activation (6) . The balance between activating and inhibitory receptor influences can be complicated by their coexpression on individual B cells. Moreover, individual cell surface receptors may possess both activating and inhibitory motifs; their differential engagement, according to ligand specificity and affinity, may trigger inhibitory and/or activating signaling pathways to calibrate effector cell responses (7) .
The recently recognized Fc receptor-like (FCRL) family includes five members that are preferentially expressed by B lineage cells, possess variable numbers of Ig domains, and have either ITIMs, ITAMs, or both in their cytoplasmic tails (8) (9) (10) (11) . FCRL5 is the largest of the FCRL transmembrane proteins. In addition to its nine Ig-like extracellular domains and a transmembrane region, FCRL5 has a noncanonical ITAM-like consensus sequence and two canonical ITIMs in the cytoplasmic domain (8) . Alternate isoforms have been identified, which include two secreted isoforms lacking transmembrane and cytoplasmic domains and a putative glycosylphosphatidylinositol-linked form, both of which lack transmembrane and cytoplasmic domains (9, 12) . FCRL5 is found on most mature B cells with the highest levels being present on naïve and memory B cells and plasma cells (13) . As for other FCRL family members, all of which have extracellular Ig domain sequences suggestive of Ig binding potential, an FCRL5 ligand has not yet been identified.
In this study, we assessed the signaling potential of FCRL5 by generating chimeric receptors encoding the intracellular domain of FCRL5 combined with the extracellular and transmembrane domains of Fc␥RIIb and evaluated their function in a B cell line. Our findings indicate that FCRL5 has the potential to inhibit BCR signaling through the recruitment of SH2 domain-containing tyrosine phosphatase 1 (SHP-1) after tyrosine phosphorylation of its two ITIMs. FCRL5 on primary memory B cells was also shown to have inhibitory potential for BCR signaling when the two receptors were coligated. These findings have implications to understanding the pathogenesis of B cell malignancies, in which aberrant FCRL5 expression is often seen.
Results

FCRL5
Signaling Inhibits BCR-Mediated Protein Tyrosine Phosphorylation. For these experiments, chimeric fusion proteins consisting of the Fc␥RIIb extracellular and transmembrane domains and the FCRL5 intracellular domain were expressed in the IgG-expressing A20-IIA1.6 mouse B cell line variant that lacks endogenous Fc␥RIIb. The inhibitory or activating potential of the FCRL intracellular domain was then examined by coligating the BCR with the chimeric Fc␥RIIb/FCRL5 receptor by using intact anti-IgG antibodies. For comparison, BCR ligation was accomplished by treating the B cells with F(abЈ) 2 fragments of the anti-IgG antibodies. By using this model system, a panel of Fc␥RIIb/FCRL5 constructs with tyrosine to phenylalanine mutations of the ITAMlike and consensus ITIM sequences were expressed to determine their potential for modulating BCR-mediated signaling (Fig. 1) . Transduced B cell populations expressing comparable levels of chimeric receptors were selected by fluorescence-activated cell sorting for use in these experiments [supporting information (SI) Fig. 7] .
BCR ligation alone, using the F(abЈ) 2 anti-Ig antibodies, induced rapid tyrosine phosphorylation of multiple intracellular proteins (Fig. 2) , whereas ligation of the WT FCRL5 fusion protein with an anti-HA antibody failed to induce tyrosine phosphorylation of the fusion protein itself or of other intracellular proteins (data not shown). However, when the BCR was coligated with the WT chimeric receptor, whole cell tyrosine phosphorylation was greatly reduced. Notably, Erk 1/2 activation was reduced relative to that seen after BCR ligation alone. After B cell stimulation with the intact anti-IgG antibodies, which bridge the BCR with Fc␥RIIb/ FCRL5, the WT chimeric receptor was phosphorylated at increasing levels over a 30 min period, whereas ligation of the BCR alone with anti-IgG F(abЈ) 2 did not induce phosphorylation of the WT chimeric molecule (Fig. 2 Bottom) . Longer chemiluminescent exposure of the Western blot membrane indicated FCRL5 tyrosine phosphorylation within the first minute after receptor ligation (data not shown). As anticipated, BCR coligation with the FFFF chimera, in which all of the cytoplasmic tyrosines were mutated, had no inhibitory effect on BCR-triggered protein tyrosine phosphorylation and Erk activation. (Fig. 3) .
A panel of chimeric receptors with tyrosine to phenylalanine mutations was used to identify the cytoplasmic tyrosine residues responsible for the inhibitory effect of FCRL5. Coligation of the BCR complex with either the Y899F or Y912F chimeric receptors failed to block inhibition of calcium mobilization. Coligation of the BCR with the Y899F/Y912F double mutant chimera also did not inhibit calcium mobilization, suggesting that neither of the tyrosines in this ITAM-like motif affect the inhibitory activity observed for FCRL5 in this B cell model. In contrast, the Y924F tyrosine mutant affected the duration of the calcium flux, truncating the response with little effect on maximal peak intensity in comparison with BCR-only induced calcium mobilization, whereas the Y954F mutant dampened the maximal peak intensity but not the duration of the calcium flux (Fig. 3) . The Y924F/Y954F double mutant restored the normal pattern of BCR-induced calcium mobilization, as was observed for the ''empty vector'' control and the FFFF quadruple mutant. Notably, the tyrosine to phenylalanine mutations in both of these consensus ITIM motifs did not result in increased calcium flux relative to the BCR-only induced flux. Collectively, these results indicate that the two ITIMs contribute to the FCRL5 inhibition of BCR-mediated calcium mobilization. Moreover, the ITAM-like (Y899/Y912) consensus region has no obvious impact on the ability of FCRL5 to modulate the BCR-mediated calcium flux.
SHP-1 Binds a Tyrosine Phosphorylated Peptide Corresponding to the
Membrane Distal ITIM of FCRL5. Having demonstrated the FCRL5 inhibitory effect on BCR-induced intracellular tyrosine phosphorylation, Erk activation, and calcium mobilization, we sought to identify the inhibitory effector molecules. In these experiments, we used biotinylated synthetic phosphopeptides corresponding to the FCRL5 ITAM-like and two ITIM sequences as affinity reagents to probe A20-IIA1.6 cell lysates (Fig. 4) . After their tyrosine phos- phorylation, ITIMs are known to serve as docking sites for molecules containing SH2 domains. Candidate inhibitory signaling molecules include the protein tyrosine phosphatases SHP-1 and SHP-2; and SHIP, an inositol polyphosphate phosphatase. When the tyrosines within ITAMs are phosphorylated by src family kinases, they may associate with Syk, a tyrosine kinase that resembles the classic src family kinases but which lacks an SH3 domain, or a signaling intermediate containing both SH2 and SH3 domains such as PLC␥2. Of these downstream effector molecules, only SHP-1 was found to bind to the most membrane-distal ITIM peptide with phosphorylated tyrosine residue 954 (Fig. 4) . None of the inhibitory candidates were found to bind the unphosphorylated synthetic peptides. with intact anti-IgG antibodies. After BCR coligation, we immunoprecipitated the FCRL5 chimeric receptors and probed Western blots of the immunoprecipitates with anti-phosphotyrosine antibodies and with antibodies to SHP-1, SHP-2, Syk, PLC␥2, and SH2-containing inositol phosphatase (SHIP). Interestingly, all of the chimeric receptors were tyrosine phosphorylated after coligation with the BCR, with the sole exception of the FFFF mutant which lacks intracellular tyrosines (Fig. 5A) . Moreover, the level of phosphorylation did not vary greatly between the mutant chimeric receptors. This analysis suggests that both the ITAM-like and ITIM regions of FCRL5 were phosphorylated during BCR coligation. When the immunoprecipitates were probed with antibodies against the candidate proteins, SHP-1 was found to be coprecipitated with the WT Fc␥RIIb/FCRL5, the Y899F and Y912F single mutants, and the Y899F/Y912F double mutant, but not with the Y924F, Y954F, Y924F/Y954F, or FFFF mutants. In contrast, the SHP-2 and SHIP phosphatases failed to associate with any of the Fc␥RIIb/ FCRL5 chimeric receptors. Association of the activating kinases Syk and PLC␥2 also was not detected (data not shown). In summary, the ability of phosphorylated tyrosines 924 and 954 to promote SHP-1 binding suggests that FCRL5 associates with SHP-1 by means of an interaction with both ITIMs to achieve its inhibitory effect on intracellular tyrosine phosphorylation and calcium mobilization. Whereas tyrosines 899 and 912 in the noncanonical ITAM are also phosphorylated after BCR coligation, they seem not to influence the FCRL5 modulating effect on BCR signaling.
Inhibition of Erk Activation Correlates with SHP-1 Association and
Inhibition of BCR-Induced Calcium Flux. The results shown in Fig. 2 indicated that Erk phosphorylation is inhibited after BCR coligation with the WT Fc␥RIIb/FCRL5 chimeric receptor. We found that the Y899F, Y912F, and Y899F/Y912F mutants were capable of inhibiting Erk phosphorylation induced by BCR ligation, in keeping with their association with SHP-1 (Fig. 5B) . In contrast, the non-SHP-1-associating Y924F, Y954F, Y924F/Y954F, and FFFF mutants were incapable of attenuating Erk activation upon coligation with the BCR. The differential ability of WT and the different Fc␥RIIb/FCRL5 mutants to alter Erk activation therefore parallels the effect on BCR-induced calcium mobilization and SHP-1 association. Because the tyrosines in the ITAM motifs of the Ig␣/Ig␤ components of the BCR complex are phosphorylated to trigger downstream signaling pathways that are activated by BCR ligation (14), they are logical targets for the FCRL5 associated SHP-1 tyrosine phosphatase. Accordingly, whereas BCR cross-linkage alone induced Ig␣ and Ig␤ phosphorylation, WT FCRL5 coligation attenuated the Ig␣ and Ig␤ tyrosine phosphorylation, and the FFFF mutant had no effect (Fig. 5C ). Ϫ , CD38 Ϫ ) were isolated by fluorescence-activated cell sorting of tonsil samples. After confirming that these cells express FCRL5 (SI Fig. 8 ), we then subjected the isolated memory B cells to stimulatory conditions in which the BCR alone was cross-linked, the FCRL5 receptor alone was cross-linked, neither was cross-linked, or the BCR was coligated with the native FCRL5 receptor. The treated cells were then fixed and permeabilized before staining with a fluorochrome-labeled anti-phosphotyrosine antibody. BCR cross-linkage alone with anti-Ig F(abЈ) 2 fragments, or BCR cross-linkage coupled with treatment by a control irrelevant antibody led to a 10-fold shift in tyrosine phosphorylation (Fig. 6B) . In contrast, cells stimulated with anti-FCRL5 F(abЈ) 2 fragments gave a signal comparable with that observed for the unstimulated population. However, tyrosine phosphorylation was significantly inhibited when FCRL5 was coligated with the BCR. When the memory B cells were pretreated with ␣-bromo-4-hydroxyacetophenone 4-hydroxyphenacyl Br, a potent SHP-1 inhibitor, the inhibition of tyrosine phosphorylation by FCRL5/BCR coligation was abrogated. With the caveat that receptor coligation was achieved by nonphysiological means, these results indicate that native FCRL5 receptors can engage SHP-1 to attenuate BCR triggered tyrosine phosphorylation after coligation of the two receptors.
Discussion
This analysis of FCRL5 signaling capability establishes its inhibitory potential for modulating the BCR-mediated activation of B cells. A dominant role is shown for the two FCLR5 ITIMs, whereas no functional activity is revealed for the ITAM-like motif. By expressing wild-type and mutated versions of Fc␥RIIb/FCRL5 chimeric receptors in B cells lacking endogenous Fc␥RIIb, we could show that the tyrosine residues in the two ITIMs are essential for the inhibitory function of FCRL5. After its coligation with the BCR, WT Fc␥RIIb/FCRL5 fusion protein inhibited calcium mobilization, whole cell tyrosine phosphorylation, and Erk activation. Conversion of tyrosines in the noncanonical ITAM-like motif to phenylalanine had no demonstrable effect on B cell activation, and mutation of the ITIM tyrosines eliminated the inhibitory effect of Our mutational analysis of the intracellular tyrosines in the FCRL5 signaling domain indicates that both ITIM tyrosines, residues 924 and 954, contribute to the attenuation of BCR signaling. Whereas a synthetic phosphopeptide mimic of the most membrane-distal ITIM could be shown to bind SHP-1, an immunoprecipitation analysis of B cell lysates suggested that both ITIMs are needed for optimal SHP-1 binding, in that mutation of the tyrosine in either of the ITIMs eliminated detectable SHP-1 association. In comparison with the calcium mobilization pattern observed after BCR ligation alone, we observed a truncated response in B cell transductants wherein tyrosine 924 was mutated and a diminished calcium flux response when tyrosine 954 in the second ITIM was mutated. The cellular tyrosine phosphorylation response was also attenuated in primary B cells after coligation of the BCR with FCRL5, and this inhibitory effect was abrogated by pretreatment with a SHP-1 inhibitor.
Whereas these findings unambiguously indicate the FCRL5 potential for inhibiting B cell activation by BCR-mediated signaling, our studies notably used artificial means to coligate the two receptors. Under physiological conditions, IgG antibodies could possibly bridge antigen-bound BCR with FCRL5, given that the two membrane distal Ig domains of FCRL5 share sequence similarity with classical Fc␥ receptors (8) and preliminary evidence has been reported for FCRL5 binding of heat-aggregated IgG (9) . However, the absence of confirmatory evidence for an Fc receptor function suggests either a relatively low IgG binding affinity or that FCRL5 has other natural ligands. An unambiguous definition of a FCRL5 ligand(s) thus remains an important goal.
Enhanced FCRL5 expression has been observed in B lineage malignancies and in B cells infected with Epstein-Barr virus (EBV) (9, 12, 15, 16) . Interestingly, FCRL5 was identified initially as an Ig superfamily gene located near the breakpoint of a chromosome 1q21 translocation event in a myeloma cell line (9) . Moreover, up-regulated FCRL5 expression is frequently associated with a 1q21 translocation abnormality in both B cell non-Hodgkins lymphomas (B-NHL) and multiple myelomas (MM) (17) (18) (19) . Patients with MM, chronic lymphocytic leukemia, and mantle cell lymphoma have been shown to have elevated levels of the soluble FCRL5 isoform. Their serum levels correspond with the tumor burden (12) , and the tumor cells express transmembrane FCRL5 as well. Cell surface FCRL5 expression is also up-regulated in EBVinfected B cells (15) . This effect is due to the formation of CBF1/RBPJ heterodimers, which dock onto binding sites in the promoter regions of FCRL5 and other target genes. In EBVinfected cells, the EBNA2 protein replaces endogenous NOTCH as the transactivator unit for CBF1 heterodimers. Whereas these clues suggest that FCRL5 over-expression contributes to the pathogenesis of B cell malignancies, our results pose the question of how heightened expression of an inhibitory receptor can foster lymphomagenesis. It would be desirable to have a mouse model to address this issue, but mice have only two FCRL1-5 gene family homologs, Fcrl1 and Fcrl5, and neither shares high sequence homology with its human counterpart. Notably, mouse FCRL5 has only one consensus ITIM (20) . Mouse models thus are unlikely to be very helpful in discerning the roles of the FCRL5 isoforms in lymphomagenesis.
FCRL5 is expressed at highest levels on mature B cells, memory B cells, and plasma cells, none of which are in a proliferative mode, and it is down-regulated on the proliferative B cells in germinal centers. The inhibitory FCRL5 on the resting B cells could participate in the delicate balance that checks cell cycle progression while allowing the basal level of constitutive BCR signaling needed for B cell survival (3). However, transcripts are expressed for multiple FCRL5 isoforms, including transmembrane, secreted, and glycosylphosphatidylinositol-anchored versions, by both normal B cells and B cell lines (9, 16) as another complicating feature in deducing the biological roles of FCRL5. The function of the soluble FCRL5 isoform, which is elevated in patients with MM, chronic lymphocytic leukemia, and mantle cell lymphoma (12) , is presently unknown. Theoretically, the soluble isoform could compete with transmembrane FCRL5 for a natural ligand thereby abrogating its inhibitory function to allow unimpeded BCR mediated proliferation and cell survival. The soluble isoform of FCRL5 potentially could also modulate a ligand-bearing immunocompetent cell needed for tumor detection and clearance. In a similar scenario, soluble FCRL5 could play a role in EBV infection by serving either to block the ligand for the transmembrane FCRL5 isoform or as a modulating factor for cytotoxic T cells that eliminate EBV infected B cells. The speculative nature of these considerations further emphasizes the need to determine the natural FCRL5 ligand(s) to understand its function in normal B cell physiology, malignancies and EBV infection.
In conclusion, our studies show that FCRL5, like FCRL4 (21, 22) , has potent inhibitory potential for BCR-mediated signaling. However, whereas FCRL4 expression is confined to a tissue-based subpopulation of memory B cells (22) , FCRL5 is expressed throughout B cell differentiation and therefore could have a broader influence on B cell responses to both endogenous and exogenous antigens.
Methods
Cells and Antibodies. A20-IIA1.6 B cells and BW5147 T cells were maintained in RPMI medium 1640 supplemented with 10% FCS, 25 mM Hepes, 2 mM L-glutamine, 50 M 2-mercaptoethanol, 100 units/ml penicillin, and 100 g/ml streptomycin at 37°C in 5.0% CO 2 . BOSC23 cells were grown in DMEM supplemented with 10% FCS, 2 mM L-glutamine, and 100 units/ml penicillin and 100 g/ml streptomycin. Anti-HA antibody 12CA5 was obtained from Roche Diagnostics (Mannheim, Germany), anti-PLC␥2, anti-SHP-1, anti-SHP-2, anti-SHIP, anti-Syk, anti-pErk (Tyr 204), and anti-eIF4E from Santa Cruz Biotechnology (Santa Cruz, CA), horseradish peroxidase-coupled anti-phosphotyrosine antibodies 4G10 from Upstate Biotechnologies (Lake Placid, NY), whole Ig and F(abЈ) 2 fragments against Ig from Zymed (Carlsbad, CA), antiphosphotyrosine PY20 R-PE-conjugated for phosphospecific flow cytometry and anti-IgD-PE and anti-CD38-FITC from BD Biosciences (San Jose, CA), and anti-Ig␤ was produced in our lab.
Production of Monoclonal Anti-FCRL5 Antibodies. Hybridoma clones producing monoclonal anti-FCRL5 antibodies were generated by hyperimmunizing BALB/c mice with BW5147 cells expressing full-length FCRL5 and extracellular FCRL5-Fc fusion protein (10 g per injection) before fusion of regional lymph node cells with the Ag8.653 plasmacytoma cell line (23) . Hybridoma supernatants were screened by ELISA for FCRL5 antibody (2A9) activity, the specificity of which was determined by cell surface immunofluorescence reactivity with BW5147 cell lines expressing FCRL1-5. Hybridomas producing anti-FCRL5 antibody were subcloned by limiting dilution, and the antibody isotype was determined by an indirect capture ELISA (Zymed). F(abЈ) 2 fragments were prepared by using the ImmunoPure F(abЈ) 2 Preparation Kit (Pierce, Rockford, IL).
Generation of Chimeric Fc␥RIIb/FCRL5 Constructs. The wild-type and mutant chimera proteins were generated by fusing the extracellular and transmembrane domains of Fc␥RIIb to the intracellular domain of FCRL5 as described (21, 24) . Site-directed mutagenesis was performed according to standard protocols. Wild-type and mutated cDNAs encoding the intracellular domain of FCRL5 were subcloned into pBluescript and verified by DNA sequencing.
